CN1929837A - 作为神经保护剂和/或神经再生剂的非免疫抑制的亲免素配体 - Google Patents

作为神经保护剂和/或神经再生剂的非免疫抑制的亲免素配体 Download PDF

Info

Publication number
CN1929837A
CN1929837A CNA2005800070342A CN200580007034A CN1929837A CN 1929837 A CN1929837 A CN 1929837A CN A2005800070342 A CNA2005800070342 A CN A2005800070342A CN 200580007034 A CN200580007034 A CN 200580007034A CN 1929837 A CN1929837 A CN 1929837A
Authority
CN
China
Prior art keywords
disease
compound
meridamycin
formula
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800070342A
Other languages
English (en)
Chinese (zh)
Inventor
E·I·格拉齐阿尼
K·庞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN1929837A publication Critical patent/CN1929837A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA2005800070342A 2004-03-02 2005-02-25 作为神经保护剂和/或神经再生剂的非免疫抑制的亲免素配体 Pending CN1929837A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54943004P 2004-03-02 2004-03-02
US60/549,430 2004-03-02

Publications (1)

Publication Number Publication Date
CN1929837A true CN1929837A (zh) 2007-03-14

Family

ID=34919492

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800070342A Pending CN1929837A (zh) 2004-03-02 2005-02-25 作为神经保护剂和/或神经再生剂的非免疫抑制的亲免素配体

Country Status (8)

Country Link
US (1) US20050197356A1 (https=)
EP (1) EP1720548A1 (https=)
JP (1) JP2007526312A (https=)
CN (1) CN1929837A (https=)
AU (1) AU2005219389A1 (https=)
BR (1) BRPI0508084A (https=)
CA (1) CA2556771A1 (https=)
WO (1) WO2005084673A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1720886A1 (en) * 2004-03-02 2006-11-15 Wyeth Macrolides and methods for producing same
MXPA06014080A (es) * 2004-06-03 2007-02-15 Wyeth Corp Agregado de genes biosinteticos para la produccion de un policetido complejo.
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
RU2008132779A (ru) 2006-03-07 2010-04-20 Вайет (Us) Аналоги меридамицина для лечения нейродегенеративных заболеваний
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
CL2007003410A1 (es) * 2006-11-28 2008-04-11 Wyeth Corp Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
US20100196355A1 (en) * 2007-01-29 2010-08-05 Wyeth Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity
JP5681719B2 (ja) 2009-09-24 2015-03-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル タウ機能不全を伴う神経障害を処置するための新規な治療ターゲットとしてのfkbp52−タウ相互作用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302016D0 (en) * 1993-02-02 1993-03-17 Sandoz Ltd Compounds
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US6242468B1 (en) * 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
US7041283B1 (en) * 2001-02-16 2006-05-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods of using immunophilin binding drugs to improve integration and survival of neuronal cell transplants

Also Published As

Publication number Publication date
WO2005084673A1 (en) 2005-09-15
CA2556771A1 (en) 2005-09-15
BRPI0508084A (pt) 2007-07-17
US20050197356A1 (en) 2005-09-08
AU2005219389A1 (en) 2005-09-15
JP2007526312A (ja) 2007-09-13
EP1720548A1 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
US20110144176A1 (en) Macrolides and methods for producing same
Jayasuriya et al. Isolation and structure elucidation of thiazomycin
MXPA97003484A (en) Macrocyclic lactone compounds and their product procedure
CN1929837A (zh) 作为神经保护剂和/或神经再生剂的非免疫抑制的亲免素配体
CN1867664A (zh) 使用新的链霉菌菌种生产他克莫司(fk-506)
US20040229323A1 (en) Process for producing anticancer agent LL-D45042
CN1165547C (zh) 与阿卡加定相关的新型羊毛硫抗生素及其制备方法和用途
CN1082052C (zh) 制备环状缩肽化合物的方法和新的环状缩肽
CN1849313A (zh) 抗生素化合物
EP2441767B1 (en) Salinosporamides and methods for use thereof
KR100226305B1 (ko) 폴리히드록시 시클로펜탄유도체, 그의 제조방법 및 그의 치료적용도
CN1422252A (zh) 受体拮抗剂趋化因子
CN1152881C (zh) 从海洋放线菌中得到的新吲哚并咔唑生物碱及其组合物和用途
JP3521110B2 (ja) 環状ペプチド化合物及びその製造方法
JPWO2005061461A1 (ja) ヒートショックプロテイン90(hsp90)ファミリー蛋白質阻害剤
MXPA06009994A (en) Macrolides and methods for producing same
CN1875012A (zh) 2-苯基苯并呋喃衍生物、其产生方法和它们的用途
MXPA06009926A (en) Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
JP2006528664A (ja) ポリエンポリケチド、その調製方法及び医薬品としてのその使用
CN1217929C (zh) 阿考霉素,其生产方法及其作为药物的用途
WO2010019659A1 (en) Pyrrolo[4,3,2-de]quinolin-8-amine compounds and methods of their preparation and use
KR20040025902A (ko) Cns 장애 치료용 의약의 제조시 티오루틴 디옥사이드및 이의 유도체의 용도 및 이의 제조방법
JP2025528388A (ja) 抗微生物性化合物、その製造方法及び使用
FI58514B (fi) Samtidig framstaellning av ergokornin ergokryptin och ergometrin med hoegt utbyte med tillhjaelp av ett fermentativt foerfarande
DK2441767T3 (en) Salinosporamider and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication